This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           July 02, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Most women don't need regular pelvic exams, new guidelines state
HealthDay News via U.S. News and World Report
The annual pelvic exam has long been a routine part of women's healthcare, but new guidelines say there's no good reason for it. The recommendations, laid out by the American College of Physicians, advise against pelvic exams for women who aren't pregnant and have no symptoms of a potential problem.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




UTERINE CANCER


ACOG issues Tamoxifen and Uterine Cancer Committee Opinion
ACOG
The American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice this month issued a new opinion, Tamoxifen and Uterine Cancer. Among several other points, the Committee recommends the following: 1) Tamoxifen use may be extended to 10 years based on new data demonstrating additional benefit and 2) Women taking tamoxifen should be informed about the risks of endometrial proliferation, endometrial hyperplasia, endometrial cancer, and uterine sarcomas. They should be encouraged to promptly report any abnormal vaginal symptoms, including bloody discharge, spotting, staining, or leukorrhea.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


IMAGING


Presurgical SPECT/CT shows more cancer than current standard
Oncology Nurse Advisor
Startling data from an international multi-center trial provide growing evidence that sentinel node imaging is more effectively accomplished with hybrid functional imaging with single photon emission computed tomography (SPECT) and computed tomography (CT) than with another molecular imaging technique called lymphoscintigraphy. This conclusion held after imaging a range of cancers displaying a variety of lymphatic drainage types associated with melanoma, an aggressive skin cancer; breast carcinoma; and malignancies of the pelvis, such as prostate and cervical cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


OVARIAN CANCER


Bevacizumab approval recommended in Europe for hard-to-treat ovarian cancer
PharmaTimes
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended that the European Commission approve the use of bevacizumab (Avastin) in combination with chemotherapy as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy. The positive opinion is based on a Phase III study showing that the addition of bevacizumab to chemotherapy reduced the risk of disease worsening or death by 62 percent.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


ODAC votes against maintenance olaparib in BRCA-positive ovarian cancer
OncLive
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 11-2 against the accelerated approval of the PARP inhibitor olaparib as a maintenance therapy for women with platinum-sensitive relapsed ovarian cancer with germline BRCA mutations. By voting no, the committee recommended waiting for results from the larger phase III SOLO-2 trial, which began enrolling in 2013. The primary endpoint of this study is progression-free survival (PFS) by RECIST criteria. Overall survival (OS) will remain a secondary endpoint, as was the case in earlier phase II trials.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.
MORE
Lantheus Proven Success
Discovering, developing and marketing innovative medical imaging agents provides a strong platform from which to bring forward new breakthrough tools for the diagnosis and management of disease. MORE


FERTILITY


No link between fertility drugs and breast, ovarian and uterine cancers
Science Codex
There is "little evidence" that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and gynecological cancers, according to the results of a substantial 30-year follow-up study. However, the extended use of clomiphene citrate was associated with a higher risk of breast cancer among women who had used the fertility drug for 12 cycles or more. Gonadotrophins, more commonly used for ovarian stimulation today, were not generally associated with any increased risk, except in a sub-group of women who remained childless after treatment.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




BREAST CANCER


T-DM1 now preferred for progressive HER2 breast cancer
Medscape (Free login required)
Trastuzumab emtansine (T-DM1) should be the new standard of care for women with HER2-positive advanced breast cancer that has progressed despite multiple lines of treatment, new research shows. Interim results from the phase 3 TH3RESA trial were published in the June issue of the Lancet Oncology. Results were previously presented at the 2013 European Cancer Congress, as reported at the time by Medscape Medical News.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

June 25, 2014
June 18, 2014
June 11, 2014
June 4, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063